Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
12,296 GBX | -0.87% | +1.54% | +16.00% |
May. 24 | Innate Pharma: five abstracts selected for ASCO | CF |
May. 24 | Adherium Partners with AstraZeneca for Hailie Smartinhaler Trial | MT |
Summary
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
- Sales forecast by analysts have been recently revised upwards.
- Analysts covering this company mostly recommend stock overweighting or purchase.
Weaknesses
- The company benefits from high valuations in earnings multiples.
- Based on current prices, the company has particularly high valuation levels.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+16.00% | 243B | B+ | ||
+38.51% | 727B | C+ | ||
+33.05% | 599B | B | ||
-6.23% | 354B | C+ | ||
+18.78% | 328B | B- | ||
+1.35% | 277B | C+ | ||
+8.09% | 205B | B- | ||
-5.77% | 203B | A+ | ||
+6.19% | 164B | C+ | ||
+0.31% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- AZN Stock
- Ratings AstraZeneca PLC